Bacterial postbiotics as promising tools to mitigate cardiometabolic diseases

Fernando F. Anhê; Benjamin A.H. Jensen; Lais Rossi Perazza; André Tchernof; Jonathan D. Schertzer; André Marette

doi:10.12997/jla.2021.10.2.123

Bacterial postbiotics as promising tools to mitigate cardiometabolic diseases

Fernando F. Anhê^*, Benjamin A.H. Jensen, Lais Rossi Perazza, André Tchernof, Jonathan D. Schertzer, André Marette

^*Corresponding author af dette arbejde

Hansen Group

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

18 Citationer (Scopus)

22 Downloads (Pure)

Abstract

Gut microbes dictate critical features of host immunometabolism. Certain bacterial components and metabolites (termed postbiotics) mitigate cardiometabolic diseases whereas others potentiate pathological processes. In this review, we discuss key aspects related to the usefulness of bacterial-related molecules strategically positioned as promising treatment strategies for cardiometabolic diseases.

Originalsprog	Engelsk
Tidsskrift	Journal of Lipid and Atherosclerosis
Vol/bind	10
Udgave nummer	2
Sider (fra-til)	123-129
Antal sider	7
ISSN	2287-2892
DOI	https://doi.org/10.12997/jla.2021.10.2.123
Status	Udgivet - 2021

Bibliografisk note

Publisher Copyright:
© 2021 The Korean Society of Lipid and Atherosclerosis.

Adgang til dokumentet

10.12997/jla.2021.10.2.123Licens: CC BY-NC

Bacterial Postbiotics as Promising Tools to Mitigate Cardiometabolic DiseasesForlagets udgivne version, 2,62 MBLicens: CC BY-NC

Citationsformater

@article{0acf88ce71024cfdb0788bbda7106899,

title = "Bacterial postbiotics as promising tools to mitigate cardiometabolic diseases",

abstract = "Gut microbes dictate critical features of host immunometabolism. Certain bacterial components and metabolites (termed postbiotics) mitigate cardiometabolic diseases whereas others potentiate pathological processes. In this review, we discuss key aspects related to the usefulness of bacterial-related molecules strategically positioned as promising treatment strategies for cardiometabolic diseases.",

keywords = "Akkermansia, Diabetes mellitus, type 2, Lipopolysaccharides, Obesity, Peptidoglycan",

author = "Anh{\^e}, {Fernando F.} and Jensen, {Benjamin A.H.} and Perazza, {Lais Rossi} and Andr{\'e} Tchernof and Schertzer, {Jonathan D.} and Andr{\'e} Marette",

note = "Publisher Copyright: {\textcopyright} 2021 The Korean Society of Lipid and Atherosclerosis.",

year = "2021",

doi = "10.12997/jla.2021.10.2.123",

language = "English",

volume = "10",

pages = "123--129",

journal = "Journal of Lipid and Atherosclerosis",

issn = "2287-2892",

publisher = "Korean Society of Lipid and Atherosclerosis",

number = "2",

}

TY - JOUR

T1 - Bacterial postbiotics as promising tools to mitigate cardiometabolic diseases

AU - Anhê, Fernando F.

AU - Jensen, Benjamin A.H.

AU - Perazza, Lais Rossi

AU - Tchernof, André

AU - Schertzer, Jonathan D.

AU - Marette, André

PY - 2021

Y1 - 2021

N2 - Gut microbes dictate critical features of host immunometabolism. Certain bacterial components and metabolites (termed postbiotics) mitigate cardiometabolic diseases whereas others potentiate pathological processes. In this review, we discuss key aspects related to the usefulness of bacterial-related molecules strategically positioned as promising treatment strategies for cardiometabolic diseases.

AB - Gut microbes dictate critical features of host immunometabolism. Certain bacterial components and metabolites (termed postbiotics) mitigate cardiometabolic diseases whereas others potentiate pathological processes. In this review, we discuss key aspects related to the usefulness of bacterial-related molecules strategically positioned as promising treatment strategies for cardiometabolic diseases.

KW - Akkermansia

KW - Diabetes mellitus, type 2

KW - Lipopolysaccharides

KW - Obesity

KW - Peptidoglycan

U2 - 10.12997/jla.2021.10.2.123

DO - 10.12997/jla.2021.10.2.123

M3 - Journal article

C2 - 34095007

AN - SCOPUS:85110143772

SN - 2287-2892

VL - 10

SP - 123

EP - 129

JO - Journal of Lipid and Atherosclerosis

JF - Journal of Lipid and Atherosclerosis

IS - 2

ER -